Definium Therapeutics (DFTX)

Executive Summary

Definium Therapeutics is a clinical-stage biotechnology company focused on developing novel psychedelic-based therapies for central nervous system (CNS) disorders, including generalized anxiety disorder (GAD), major depressive disorder (MDD), ADHD, addiction, and autism spectrum disorder. Despite an original description targeting oncology and autoimmune diseases, the company's pipeline is entirely centered on psychedelic compounds such as MM120 (LSD d-tartrate), 18-MC, and MM402 (R-MDMA). Definium's lead programs are in Phase 3 trials for GAD and MDD, with ongoing recruitment and estimated completion in late 2026 and mid-2027, respectively. The company also has Phase 2 data for ADHD and is exploring autism with MM402. With a market capitalization of approximately $2.6 billion, Definium is positioned in the competitive psychedelic therapeutics space, facing regulatory, safety, and differentiation risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 GAD Top-Line Data Readout (MM120)60% success
• H1 2027Phase 3 MDD Trial Completion and Data (MM120)55% success
• Q3 2026Phase 2 ADHD Data Presentation (MM120)70% success